Sarah Cannon Cancer Institute

Nashville, Tennessee 37203

5 studies enrolling now · 6 studies all time

What they study most

AML - Acute Myeloid Leukemia, Breast Cancer, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia (CMML), Esophageal Cancer, Gastric Cancer, Hematologic Neoplasms, Hepatocellular Cancer, High-risk Myelodysplastic Syndrome, Kidney Cancer, Mesothelioma, Metastatic Pancreas Adenocarcinoma

Studies at this site

• A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms — Recruiting now
• A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies — Recruiting now
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma — Available (expanded access)
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors — Stopped early